SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the launch of its product Vesele®, approved by Health Canada for the increase in vasodilation through nitric oxide production, in Canada. Vesele® is available in that country directly through the Company’s website and through its Beyond Human™ marketing and sales platform.
“We are very happy to announce the launch of Vesele® in Canada,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “Vesele® represents the third product launched through our own sales and marketing commercial efforts in Canada in addition to Apeaz® and Xyralid® and is our seventh product on the Canadian market including Zestra®, Zestra Glide® and Uxor™ (EjectDelay™) marketed by Orimed Pharma and UriVarx® through our partnership with Acerus Pharmaceuticals Corporation.”
About Vesele®
Vesele® is approved by Health Canada as a Natural Health Product (“NHP”) to increase vasodilation through nitric oxide production. Vasodilation is the main mechanism used by many approved drugs including Viagra and Cialis and others for erectile dysfunction. Vesele® is a proprietary clinically tested oral formulation of L-Arginine and L-Citrulline with the natural absorption enhancer Bioperine® in patients suffering from sexual dysfunction. Vesele® was formulated to increase blood flow and nitric oxide production.
As previously reported, a U.S. human clinical use survey was completed on Vesele® to evaluate erectile dysfunction and sexual satisfaction in men using Vesele® twice daily for up to four months with the following favorable results:
1. 49.5% increase in erection hardness
2. 44.5% increase in erection maintenance
3. 34.6% increase in desire for sexual activity
4. 34.1% increase the ability to satisfy the partner
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; www.apeaz.com; and www.diabsens.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the Vesele® product in Canada, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
